Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Where is US FDA's overdue 'animal rule' guidance for drugs?

This article was originally published in SRA

Executive Summary

The US Food and Drug Administration has been called on to explain when its long-overdue drug guidance on the so-called animal rule is likely to be finalized.

You may also be interested in...



Flexible 'Menu' Of Antibacterial Development Options Suggested By US FDA Panel

FDA should consider allowing sponsors in challenging area of single species antibacterials more flexibility in study designs, advisory committee suggests, despite disagreement over approaches such as animal models and non-inferiority trials.

Antibacterial Drugs: FDA Panel To Explore Approval Path For Single-Species Agents

US agency’s advisory committee will weigh the pros and cons of five possible development and regulatory pathways, with a specific focus on animal models.

Antibacterial Development: Industry Cautious About Role Of Animal Models

Payers and prescribers, not just the US FDA, need to understand the basis of approval, John Rex says.

UsernamePublicRestriction

Register

PS118123

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel